Interplay between Serotonin 5‐ HT 1A and 5‐ HT 7 Receptors in Depressive Disorders
Summary Serotonin (5‐hydroxytryptamine or 5‐ HT ) is an important neurotransmitter regulating a wide range of physiological and pathological functions via activation of heterogeneously expressed 5‐ HT receptors. Besides the important role of 5‐ HT receptors in the pathogenesis of depressive disorder...
Saved in:
| Published in | CNS neuroscience & therapeutics Vol. 20; no. 7; pp. 582 - 590 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
John Wiley and Sons Inc
01.07.2014
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Serotonin (5‐hydroxytryptamine or 5‐
HT
) is an important neurotransmitter regulating a wide range of physiological and pathological functions via activation of heterogeneously expressed 5‐
HT
receptors. Besides the important role of 5‐
HT
receptors in the pathogenesis of depressive disorders and in their clinical medications, underlying mechanisms are far from being completely understood. This review focuses on possible cross talk between two serotonin receptors, 5‐
HT
1A
and the 5‐
HT
7
. Although these receptors are highly co‐expressed in brain regions implicated in depression, and most agonists developed for the 5‐
HT
1A
or 5‐
HT
7
receptors have cross‐reactivity, their functional interaction has not been yet established. It has been recently shown that 5‐
HT
1A
and 5‐
HT
7
receptors form homo‐ and heterodimers both
in vitro
and
in vivo
. From the functional point of view, heterodimerization has been shown to play an important role in regulation of receptor‐mediated signaling and internalization, suggesting the implication of heterodimerization in the development and maintenance of depression. Interaction between these receptors is also of clinical interest, because both receptors represent an important pharmacological target for the treatment of depression and anxiety. |
|---|---|
| AbstractList | Serotonin (5‐hydroxytryptamine or 5‐
HT
) is an important neurotransmitter regulating a wide range of physiological and pathological functions via activation of heterogeneously expressed 5‐
HT
receptors. Besides the important role of 5‐
HT
receptors in the pathogenesis of depressive disorders and in their clinical medications, underlying mechanisms are far from being completely understood. This review focuses on possible cross talk between two serotonin receptors, 5‐
HT
1A
and the 5‐
HT
7
. Although these receptors are highly co‐expressed in brain regions implicated in depression, and most agonists developed for the 5‐
HT
1A
or 5‐
HT
7
receptors have cross‐reactivity, their functional interaction has not been yet established. It has been recently shown that 5‐
HT
1A
and 5‐
HT
7
receptors form homo‐ and heterodimers both
in vitro
and
in vivo
. From the functional point of view, heterodimerization has been shown to play an important role in regulation of receptor‐mediated signaling and internalization, suggesting the implication of heterodimerization in the development and maintenance of depression. Interaction between these receptors is also of clinical interest, because both receptors represent an important pharmacological target for the treatment of depression and anxiety. Summary Serotonin (5‐hydroxytryptamine or 5‐ HT ) is an important neurotransmitter regulating a wide range of physiological and pathological functions via activation of heterogeneously expressed 5‐ HT receptors. Besides the important role of 5‐ HT receptors in the pathogenesis of depressive disorders and in their clinical medications, underlying mechanisms are far from being completely understood. This review focuses on possible cross talk between two serotonin receptors, 5‐ HT 1A and the 5‐ HT 7 . Although these receptors are highly co‐expressed in brain regions implicated in depression, and most agonists developed for the 5‐ HT 1A or 5‐ HT 7 receptors have cross‐reactivity, their functional interaction has not been yet established. It has been recently shown that 5‐ HT 1A and 5‐ HT 7 receptors form homo‐ and heterodimers both in vitro and in vivo . From the functional point of view, heterodimerization has been shown to play an important role in regulation of receptor‐mediated signaling and internalization, suggesting the implication of heterodimerization in the development and maintenance of depression. Interaction between these receptors is also of clinical interest, because both receptors represent an important pharmacological target for the treatment of depression and anxiety. |
| Author | Lacivita, Enza Ponimaskin, Evgeni G. Popova, Nina K. Naumenko, Vladimir S. Leopoldo, Marcello |
| AuthorAffiliation | 1 Department of Behavioral Neurogenomics Institute of Cytology and Genetics Novosibirsk Russia 2 Dipartimento di Farmacia‐Scienze del Farmaco Università degli Studi di Bari ‘Aldo Moro’ Bari Italy 3 Cellular Neurophysiology Hannover Medical School Hannover Germany |
| AuthorAffiliation_xml | – name: 2 Dipartimento di Farmacia‐Scienze del Farmaco Università degli Studi di Bari ‘Aldo Moro’ Bari Italy – name: 3 Cellular Neurophysiology Hannover Medical School Hannover Germany – name: 1 Department of Behavioral Neurogenomics Institute of Cytology and Genetics Novosibirsk Russia |
| Author_xml | – sequence: 1 givenname: Vladimir S. surname: Naumenko fullname: Naumenko, Vladimir S. organization: Department of Behavioral Neurogenomics Institute of Cytology and Genetics Novosibirsk Russia – sequence: 2 givenname: Nina K. surname: Popova fullname: Popova, Nina K. organization: Department of Behavioral Neurogenomics Institute of Cytology and Genetics Novosibirsk Russia – sequence: 3 givenname: Enza surname: Lacivita fullname: Lacivita, Enza organization: Dipartimento di Farmacia‐Scienze del Farmaco Università degli Studi di Bari ‘Aldo Moro’ Bari Italy – sequence: 4 givenname: Marcello surname: Leopoldo fullname: Leopoldo, Marcello organization: Dipartimento di Farmacia‐Scienze del Farmaco Università degli Studi di Bari ‘Aldo Moro’ Bari Italy – sequence: 5 givenname: Evgeni G. surname: Ponimaskin fullname: Ponimaskin, Evgeni G. organization: Cellular Neurophysiology Hannover Medical School Hannover Germany |
| BookMark | eNpVkM9KAzEQxoNU7B89-Aa5etia7CabzUUordpCQdDqNWSzE11pkyVZK735CD6jT-JqpeBcZj5m5jfMN0Q95x0gdE7JmHZxaVwc0zRl4ggNqOA84ZLJ3qHOSB8NY3wlJE8LWZygfspkxkUhBuhp4VoIzVrvcAntO4DDDxB8613tMP_6-MTzFaYTrF11kALfg4Gm9SHibmoGTYAY6y3gWR19qCDEU3Rs9TrC2V8eoceb69V0nizvbhfTyTIxNJUy0VTanEltaCG6R0hpbMZyznglJQAhjBNraSqkLEEKk-dG8oJWPK9yBraw2Qhd7bnNW7mByoBrg16rJtQbHXbK61r977j6RT37requZkTIDnCxB5jgYwxgD7uUqB9zVWeu-jU3-wYg-m48 |
| CitedBy_id | crossref_primary_10_1002_med_22049 crossref_primary_10_1080_14737175_2024_2333394 crossref_primary_10_3390_ijms21228784 crossref_primary_10_3390_ijms222413319 crossref_primary_10_1134_S1819712420040078 crossref_primary_10_1371_journal_pone_0142499 crossref_primary_10_1080_14728222_2019_1572747 crossref_primary_10_2174_0929867326666190620095623 crossref_primary_10_3390_ijms242216416 crossref_primary_10_1017_S1092852915000425 crossref_primary_10_1038_s41380_019_0397_1 crossref_primary_10_2174_1874467213666200422090135 crossref_primary_10_3390_brainsci12060747 crossref_primary_10_1016_j_bbr_2016_04_050 crossref_primary_10_1007_s42535_021_00308_9 crossref_primary_10_1016_j_biopha_2017_12_053 crossref_primary_10_1016_j_pharmthera_2021_107842 crossref_primary_10_1134_S0006297917030099 crossref_primary_10_1134_S0006297923120064 crossref_primary_10_7868_S0032874X23020011 crossref_primary_10_1155_2015_846589 crossref_primary_10_1016_j_neulet_2017_06_053 crossref_primary_10_3390_molecules27217270 crossref_primary_10_3390_ph12020099 crossref_primary_10_1016_j_bmc_2016_05_053 crossref_primary_10_1016_j_cophys_2018_12_012 crossref_primary_10_1080_14728222_2018_1452912 crossref_primary_10_1021_acsomega_3c01283 crossref_primary_10_1124_pr_118_015552 crossref_primary_10_1016_j_bmc_2016_12_039 crossref_primary_10_2174_1570159X20666220327221830 crossref_primary_10_1515_revneuro_2023_0055 crossref_primary_10_3390_molecules26113348 crossref_primary_10_1371_journal_pone_0156986 crossref_primary_10_1016_j_pharmthera_2021_107872 crossref_primary_10_1016_j_biopha_2019_109408 crossref_primary_10_1016_j_bmcl_2018_04_059 crossref_primary_10_1111_jnc_13962 crossref_primary_10_3389_fphar_2015_00162 crossref_primary_10_1080_17460441_2023_2214361 crossref_primary_10_1016_j_bmcl_2016_06_080 crossref_primary_10_2174_1389450124666230425233727 crossref_primary_10_1016_j_neulet_2018_09_013 crossref_primary_10_3389_fphar_2018_01289 crossref_primary_10_1016_j_bbr_2020_112932 crossref_primary_10_1016_j_heliyon_2019_e02890 crossref_primary_10_1039_C8NJ00089A crossref_primary_10_1016_j_mcn_2017_09_009 crossref_primary_10_1021_acs_jmedchem_7b01898 crossref_primary_10_13160_ricns_2016_9_2_128 crossref_primary_10_2174_0929867329666220317121551 crossref_primary_10_1007_s12035_019_01690_x crossref_primary_10_1134_S1819712421010098 crossref_primary_10_1515_revneuro_2016_0079 crossref_primary_10_1134_S1819712420020051 crossref_primary_10_1016_j_bbr_2022_114168 crossref_primary_10_1038_srep12584 crossref_primary_10_1134_S0026893317020133 crossref_primary_10_1152_ajprenal_00077_2018 crossref_primary_10_1016_j_celrep_2024_114140 crossref_primary_10_1038_s41386_020_0775_z crossref_primary_10_3390_ijms232113308 crossref_primary_10_1111_brv_12585 crossref_primary_10_3389_fphar_2018_00157 crossref_primary_10_1016_j_bioorg_2023_106737 crossref_primary_10_1134_S002689331705020X crossref_primary_10_1021_acsomega_9b00633 crossref_primary_10_1016_j_ejmech_2021_113243 crossref_primary_10_1113_JP280610 crossref_primary_10_1177_0897190021997011 crossref_primary_10_1002_jnr_25055 crossref_primary_10_1134_S0026893316060108 crossref_primary_10_1016_j_neuroscience_2019_10_015 crossref_primary_10_31857_S0320972523120059 crossref_primary_10_3390_molecules24081609 crossref_primary_10_1021_acs_jcim_9b00926 crossref_primary_10_4155_ppa_14_35 crossref_primary_10_1007_s10519_015_9714_x crossref_primary_10_1134_S2079059717010105 crossref_primary_10_3390_biom11121914 crossref_primary_10_1007_s12035_017_0536_0 crossref_primary_10_1016_j_alcohol_2020_04_002 crossref_primary_10_1155_2015_726471 crossref_primary_10_3390_ijms23158814 crossref_primary_10_1016_j_neuropharm_2015_05_012 crossref_primary_10_1039_C9FO01630A crossref_primary_10_1002_syn_22059 crossref_primary_10_1016_j_ejmech_2023_115414 crossref_primary_10_3389_fnbeh_2020_00040 |
| Cites_doi | 10.1385/JMN:26:2-3:209 10.1016/j.neuropharm.2012.06.061 10.1007/BF00216019 10.1378/chest.115.5.1397 10.1016/j.tips.2004.07.002 10.1007/s00213-004-1950-3 10.1016/S1054-3589(08)60178-7 10.1007/s10571-005-3969-3 10.1016/j.biopsych.2003.09.017 10.1016/S0169-328X(97)00317-3 10.1523/JNEUROSCI.23-25-08788.2003 10.1038/sj.bjp.0703357 10.1007/s10719-008-9187-8 10.1016/S0021-9258(17)46830-X 10.1007/s00213-010-2001-x 10.1111/j.1601-183X.2007.00352.x 10.1523/JNEUROSCI.2765-11.2012 10.1016/S0969-8051(00)00119-0 10.1002/jnr.20456 10.1016/S0006-3223(02)01643-8 10.1111/j.1471-4159.1985.tb07155.x 10.1097/00041444-199623000-00002 10.1016/S0028-3908(98)00070-7 10.1152/jn.00136.2005 10.1038/sj.bjp.0705290 10.1016/j.biopsych.2012.06.008 10.1016/j.neuropharm.2004.11.015 10.1523/JNEUROSCI.20-22-j0007.2000 10.1021/jp201458h 10.1038/sj.bjp.0701946 10.1001/archpsyc.63.4.396 10.1001/archpsyc.57.2.174 10.1038/335358a0 10.1016/S0006-8993(96)01131-6 10.1016/S0893-133X(01)00310-4 10.1038/mp.2012.93 10.1016/0165-6147(93)90016-D 10.1523/JNEUROSCI.18-18-07394.1998 10.1002/syn.20883 10.1073/pnas.0501112102 10.1016/0888-7543(91)90317-8 10.1523/JNEUROSCI.5113-03.2004 10.1016/0014-2999(93)90280-U 10.1038/sj.bjp.0707571 10.1073/pnas.92.14.6542 10.1016/S0028-3908(99)00010-6 10.1016/j.bbr.2008.05.016 10.1038/329075a0 10.1016/0006-2952(93)90243-P 10.1124/jpet.112.193995 10.1016/0014-2999(96)00086-6 10.1016/j.bbamcr.2008.02.021 10.1016/j.bpj.2010.12.3692 10.1016/j.pain.2008.11.009 10.1097/00041444-199906000-00010 10.1073/pnas.0337340100 10.1111/j.1749-6632.1990.tb16877.x 10.1002/hipo.20940 10.1016/j.pnpbp.2009.01.006 10.1016/S0006-8993(02)03727-7 10.1016/j.pharmthera.2010.08.013 10.1007/s00213-013-3247-x 10.1007/BF01253058 10.1038/370143a0 10.1074/jbc.M401923200 10.1016/S0024-3205(01)01318-2 10.1523/JNEUROSCI.21-21-08378.2001 10.1016/0028-3908(94)90059-0 10.1016/j.ejphar.2005.06.012 10.1016/S0893-133X(99)00041-X 10.1046/j.1471-4159.1997.68041372.x 10.1016/j.brainres.2010.09.103 10.1124/mol.110.069278 10.1016/S0006-8993(97)01127-X 10.1124/mol.64.6.1317 10.1124/mol.106.022756 10.1038/sj.npp.1300901 10.1007/s00213-006-0490-4 10.1177/1073858404267382 10.1016/S0960-894X(02)00690-X 10.1074/jbc.M112216200 10.1124/jpet.103.061796 10.1016/j.neulet.2010.06.036 10.1016/j.bbr.2007.12.012 10.1016/0014-2999(83)90230-3 10.1073/pnas.90.18.8547 10.1021/jm970519e 10.1046/j.1471-4159.2003.01987.x 10.1016/j.tips.2009.11.008 10.1017/S1461145704004699 10.1016/j.pnpbp.2012.08.005 10.1016/S0006-8993(99)01311-6 10.1124/jpet.104.081919 10.1038/nature06612 10.1016/0896-6273(93)90149-L 10.1242/jcs.101337 10.1007/BF00176767 10.1074/jbc.273.28.17469 10.1016/0166-4328(96)00118-0 10.1038/sj.tpj.6500340 10.1007/s00221-013-3694-y 10.1124/mol.112.079137 10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A 10.1016/S0021-9258(19)39437-2 10.1016/j.ejphar.2004.01.031 10.1046/j.1471-4159.1999.0722238.x 10.1016/j.neuropharm.2011.08.022 10.1021/jm991151j 10.1016/0006-8993(90)91759-A 10.1016/S0165-6147(00)01799-5 10.1073/pnas.0906695106 10.1074/jbc.275.11.8161 10.1038/sj.bjp.0705178 10.2174/1568007043482633 10.1016/j.tips.2005.01.004 10.1523/JNEUROSCI.13-12-05164.1993 10.1016/S0021-9258(19)49479-9 10.1016/j.neuron.2009.12.003 10.1016/j.biopsych.2005.05.012 10.1523/JNEUROSCI.1790-05.2005 |
| ContentType | Journal Article |
| Copyright | 2014 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2014 John Wiley & Sons Ltd |
| DBID | AAYXX CITATION 5PM |
| DOI | 10.1111/cns.12247 |
| DatabaseName | CrossRef PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | V.S. Naumenko et al |
| EISSN | 1755-5949 |
| EndPage | 590 |
| ExternalDocumentID | 10_1111_cns_12247 |
| GrantInformation_xml | – fundername: Deutsche Forschungsgemeinschaft grantid: PO732 – fundername: Cluster of Excellence REBIRTH grantid: 6.7 – fundername: Russian Foundation for Basic Research grantid: 12‐04‐00082 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 24P 29B 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8AO 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAHHS AAONW AAYXX AAZKR ABCQN ABDBF ABEML ABIVO ABPVW ABUWG ACCFJ ACGFS ACMXC ACPRK ACSCC ACXQS ADBBV ADEOM ADIZJ ADKYN ADPDF ADZMN ADZOD AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFKRA AFPKN AFPWT AFZJQ AHMBA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AOIJS ATUGU AVUZU AZBYB AZVAB BAFTC BBNVY BCNDV BENPR BFHJK BHBCM BHPHI BMXJE BROTX BRXPI BY8 CAG CCPQU CITATION COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DU5 EBC EBD EBS EJD EMB EMOBN ESX F00 F01 F04 F5P FUBAC FYUFA G-S G.N GODZA GROUPED_DOAJ H.X HCIFZ HF~ HMCUK HYE HZ~ IAO IHR INH ITC IX1 J0M LC2 LC3 LH4 LITHE LOXES LP6 LP7 LUTES LW6 M7P MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD OVEED P2W P2X P2Z P4B P4D PIMPY PQQKQ Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ SV3 TEORI TUS UB1 UKHRP W8V W99 WBKPD WIH WIJ WIK WIN WNSPC WOHZO WQJ WRC WXI WYISQ XG1 ~IA ~WT 5PM |
| ID | FETCH-LOGICAL-c1299-a19f649ac1871110bcf346545d99ee00450ff12799be97c66c9581d56d64ef8f3 |
| IEDL.DBID | RPM |
| ISSN | 1755-5930 |
| IngestDate | Tue Sep 17 21:16:49 EDT 2024 Thu Sep 26 17:09:27 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1299-a19f649ac1871110bcf346545d99ee00450ff12799be97c66c9581d56d64ef8f3 |
| PMID | 24935787 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6493079 crossref_primary_10_1111_cns_12247 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-07-00 |
| PublicationDateYYYYMMDD | 2014-07-01 |
| PublicationDate_xml | – month: 07 year: 2014 text: 2014-07-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken |
| PublicationTitle | CNS neuroscience & therapeutics |
| PublicationYear | 2014 |
| Publisher | John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley and Sons Inc |
| References | e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_40_1 e_1_2_10_109_1 e_1_2_10_131_1 e_1_2_10_70_1 e_1_2_10_93_1 e_1_2_10_2_1 e_1_2_10_74_1 e_1_2_10_97_1 e_1_2_10_116_1 e_1_2_10_6_1 e_1_2_10_55_1 e_1_2_10_14_1 e_1_2_10_37_1 Azmitia PM (e_1_2_10_9_1) 1995 e_1_2_10_78_1 e_1_2_10_112_1 e_1_2_10_13_1 e_1_2_10_32_1 Millan MJ (e_1_2_10_127_1) 1994; 268 e_1_2_10_51_1 Erdmann J (e_1_2_10_42_1) 1996; 1 e_1_2_10_120_1 Plassat JL (e_1_2_10_36_1) 1993; 44 e_1_2_10_82_1 e_1_2_10_128_1 e_1_2_10_29_1 e_1_2_10_86_1 Dourish CT (e_1_2_10_56_1) 1987 e_1_2_10_105_1 e_1_2_10_124_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_67_1 e_1_2_10_101_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_41_1 Riad M (e_1_2_10_26_1) 2001; 21 Stockmeier CA (e_1_2_10_31_1) 1998; 18 e_1_2_10_90_1 e_1_2_10_71_1 e_1_2_10_117_1 e_1_2_10_94_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_75_1 e_1_2_10_113_1 e_1_2_10_38_1 e_1_2_10_98_1 e_1_2_10_79_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_10_1 e_1_2_10_33_1 Popova NK (e_1_2_10_5_1) 2013; 24 e_1_2_10_121_1 Albert PR (e_1_2_10_18_1) 1990; 265 e_1_2_10_60_1 e_1_2_10_106_1 e_1_2_10_129_1 e_1_2_10_64_1 e_1_2_10_102_1 e_1_2_10_125_1 e_1_2_10_49_1 e_1_2_10_87_1 e_1_2_10_68_1 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_69_1 Yoshioka M (e_1_2_10_83_1) 1992; 260 e_1_2_10_110_1 e_1_2_10_91_1 e_1_2_10_72_1 e_1_2_10_95_1 e_1_2_10_118_1 e_1_2_10_4_1 e_1_2_10_53_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_76_1 e_1_2_10_99_1 e_1_2_10_8_1 e_1_2_10_57_1 e_1_2_10_58_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_30_1 Beck SG (e_1_2_10_111_1) 1992; 263 e_1_2_10_119_1 e_1_2_10_80_1 e_1_2_10_61_1 e_1_2_10_84_1 e_1_2_10_107_1 e_1_2_10_126_1 e_1_2_10_27_1 e_1_2_10_65_1 e_1_2_10_88_1 e_1_2_10_103_1 e_1_2_10_122_1 e_1_2_10_24_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_108_1 Jolas T (e_1_2_10_114_1) 1994; 268 Johansson L (e_1_2_10_63_1) 1997; 283 Charest A (e_1_2_10_19_1) 1993; 13 e_1_2_10_130_1 e_1_2_10_92_1 e_1_2_10_73_1 e_1_2_10_115_1 e_1_2_10_96_1 e_1_2_10_54_1 e_1_2_10_17_1 e_1_2_10_77_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_59_1 e_1_2_10_50_1 e_1_2_10_81_1 e_1_2_10_62_1 e_1_2_10_104_1 e_1_2_10_85_1 e_1_2_10_28_1 e_1_2_10_66_1 e_1_2_10_100_1 e_1_2_10_123_1 e_1_2_10_47_1 e_1_2_10_89_1 |
| References_xml | – ident: e_1_2_10_94_1 doi: 10.1385/JMN:26:2-3:209 – ident: e_1_2_10_70_1 doi: 10.1016/j.neuropharm.2012.06.061 – ident: e_1_2_10_76_1 doi: 10.1007/BF00216019 – ident: e_1_2_10_82_1 doi: 10.1378/chest.115.5.1397 – ident: e_1_2_10_86_1 doi: 10.1016/j.tips.2004.07.002 – ident: e_1_2_10_122_1 doi: 10.1007/s00213-004-1950-3 – ident: e_1_2_10_4_1 doi: 10.1016/S1054-3589(08)60178-7 – ident: e_1_2_10_25_1 doi: 10.1007/s10571-005-3969-3 – ident: e_1_2_10_120_1 doi: 10.1016/j.biopsych.2003.09.017 – volume: 283 start-page: 216 year: 1997 ident: e_1_2_10_63_1 article-title: The pharmacological characterization of a novel selective 5‐hydroxytryptamine1A receptor antagonist, NAD‐299 publication-title: J Pharmacol Exp Ther contributor: fullname: Johansson L – ident: e_1_2_10_10_1 doi: 10.1016/S0169-328X(97)00317-3 – ident: e_1_2_10_14_1 doi: 10.1523/JNEUROSCI.23-25-08788.2003 – ident: e_1_2_10_73_1 doi: 10.1038/sj.bjp.0703357 – ident: e_1_2_10_101_1 doi: 10.1007/s10719-008-9187-8 – ident: e_1_2_10_65_1 doi: 10.1016/S0021-9258(17)46830-X – ident: e_1_2_10_105_1 doi: 10.1007/s00213-010-2001-x – ident: e_1_2_10_80_1 doi: 10.1111/j.1601-183X.2007.00352.x – ident: e_1_2_10_37_1 doi: 10.1523/JNEUROSCI.2765-11.2012 – ident: e_1_2_10_121_1 doi: 10.1016/S0969-8051(00)00119-0 – ident: e_1_2_10_79_1 doi: 10.1002/jnr.20456 – ident: e_1_2_10_12_1 doi: 10.1016/S0006-3223(02)01643-8 – ident: e_1_2_10_57_1 doi: 10.1111/j.1471-4159.1985.tb07155.x – ident: e_1_2_10_78_1 doi: 10.1097/00041444-199623000-00002 – volume: 268 start-page: 1432 year: 1994 ident: e_1_2_10_114_1 article-title: Central pre‐ and postsynaptic 5‐HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine publication-title: J Pharmacol Exp Ther contributor: fullname: Jolas T – ident: e_1_2_10_45_1 doi: 10.1016/S0028-3908(98)00070-7 – ident: e_1_2_10_52_1 doi: 10.1152/jn.00136.2005 – ident: e_1_2_10_75_1 doi: 10.1038/sj.bjp.0705290 – ident: e_1_2_10_68_1 doi: 10.1016/j.biopsych.2012.06.008 – ident: e_1_2_10_126_1 doi: 10.1016/j.neuropharm.2004.11.015 – ident: e_1_2_10_95_1 doi: 10.1523/JNEUROSCI.20-22-j0007.2000 – ident: e_1_2_10_103_1 doi: 10.1021/jp201458h – ident: e_1_2_10_74_1 doi: 10.1038/sj.bjp.0701946 – ident: e_1_2_10_32_1 doi: 10.1001/archpsyc.63.4.396 – ident: e_1_2_10_123_1 doi: 10.1001/archpsyc.57.2.174 – ident: e_1_2_10_17_1 doi: 10.1038/335358a0 – ident: e_1_2_10_28_1 doi: 10.1016/S0006-8993(96)01131-6 – ident: e_1_2_10_30_1 doi: 10.1016/S0893-133X(01)00310-4 – ident: e_1_2_10_33_1 doi: 10.1038/mp.2012.93 – ident: e_1_2_10_2_1 doi: 10.1016/0165-6147(93)90016-D – volume: 18 start-page: 7394 year: 1998 ident: e_1_2_10_31_1 article-title: Increase in serotonin‐1A autoreceptors in the midbrain of suicide victims with major depression‐postmortem evidence for decreased serotonin activity publication-title: J Neurosci doi: 10.1523/JNEUROSCI.18-18-07394.1998 contributor: fullname: Stockmeier CA – ident: e_1_2_10_29_1 doi: 10.1002/syn.20883 – ident: e_1_2_10_91_1 doi: 10.1073/pnas.0501112102 – ident: e_1_2_10_20_1 doi: 10.1016/0888-7543(91)90317-8 – ident: e_1_2_10_116_1 doi: 10.1523/JNEUROSCI.5113-03.2004 – ident: e_1_2_10_60_1 doi: 10.1016/0014-2999(93)90280-U – ident: e_1_2_10_92_1 doi: 10.1038/sj.bjp.0707571 – ident: e_1_2_10_108_1 doi: 10.1073/pnas.92.14.6542 – ident: e_1_2_10_3_1 doi: 10.1016/S0028-3908(99)00010-6 – ident: e_1_2_10_15_1 doi: 10.1016/j.bbr.2008.05.016 – ident: e_1_2_10_16_1 doi: 10.1038/329075a0 – ident: e_1_2_10_128_1 doi: 10.1016/0006-2952(93)90243-P – ident: e_1_2_10_6_1 doi: 10.1124/jpet.112.193995 – ident: e_1_2_10_61_1 doi: 10.1016/0014-2999(96)00086-6 – ident: e_1_2_10_100_1 doi: 10.1016/j.bbamcr.2008.02.021 – ident: e_1_2_10_102_1 doi: 10.1016/j.bpj.2010.12.3692 – ident: e_1_2_10_71_1 doi: 10.1016/j.pain.2008.11.009 – ident: e_1_2_10_23_1 doi: 10.1097/00041444-199906000-00010 – ident: e_1_2_10_81_1 doi: 10.1073/pnas.0337340100 – ident: e_1_2_10_112_1 doi: 10.1111/j.1749-6632.1990.tb16877.x – ident: e_1_2_10_69_1 doi: 10.1002/hipo.20940 – ident: e_1_2_10_124_1 doi: 10.1016/j.pnpbp.2009.01.006 – ident: e_1_2_10_110_1 doi: 10.1016/S0006-8993(02)03727-7 – volume: 24 start-page: 191 year: 2013 ident: e_1_2_10_5_1 article-title: 5‐HT1A receptor as a key player in the brain 5‐HT system publication-title: Rev Neurosci contributor: fullname: Popova NK – volume: 263 start-page: 350 year: 1992 ident: e_1_2_10_111_1 article-title: Comparison of 5‐hydroxytryptamine1A‐mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells publication-title: J Pharmacol Exp Ther contributor: fullname: Beck SG – ident: e_1_2_10_41_1 doi: 10.1016/j.pharmthera.2010.08.013 – ident: e_1_2_10_67_1 doi: 10.1007/s00213-013-3247-x – ident: e_1_2_10_77_1 doi: 10.1007/BF01253058 – ident: e_1_2_10_109_1 doi: 10.1038/370143a0 – start-page: 443 volume-title: Psychopharmacology: The fourth generation of progress year: 1995 ident: e_1_2_10_9_1 contributor: fullname: Azmitia PM – ident: e_1_2_10_99_1 doi: 10.1074/jbc.M401923200 – ident: e_1_2_10_46_1 doi: 10.1016/S0024-3205(01)01318-2 – volume: 21 start-page: 8378 year: 2001 ident: e_1_2_10_26_1 article-title: Agonist‐induced internalization of serotonin‐1a receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors) publication-title: J Neurosci doi: 10.1523/JNEUROSCI.21-21-08378.2001 contributor: fullname: Riad M – ident: e_1_2_10_66_1 doi: 10.1016/0028-3908(94)90059-0 – ident: e_1_2_10_53_1 doi: 10.1016/j.ejphar.2005.06.012 – ident: e_1_2_10_125_1 doi: 10.1016/S0893-133X(99)00041-X – ident: e_1_2_10_43_1 doi: 10.1046/j.1471-4159.1997.68041372.x – ident: e_1_2_10_49_1 doi: 10.1016/j.brainres.2010.09.103 – ident: e_1_2_10_106_1 doi: 10.1124/mol.110.069278 – ident: e_1_2_10_27_1 doi: 10.1016/S0006-8993(97)01127-X – ident: e_1_2_10_98_1 doi: 10.1124/mol.64.6.1317 – volume: 1 start-page: 392 year: 1996 ident: e_1_2_10_42_1 article-title: The human serotonin 7 (5‐HT7) receptor gene: Genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder publication-title: Mol Psychiatry contributor: fullname: Erdmann J – ident: e_1_2_10_117_1 doi: 10.1124/mol.106.022756 – ident: e_1_2_10_44_1 doi: 10.1038/sj.npp.1300901 – ident: e_1_2_10_64_1 doi: 10.1007/s00213-006-0490-4 – volume: 268 start-page: 337 year: 1994 ident: e_1_2_10_127_1 article-title: Novel benzodioxopiperazines acting as antagonists at postsynaptic 5‐HT1A receptors and as agonists at 5‐HT1A autoreceptors: A comparative pharmacological characterization with proposed 5‐HT1A antagonists publication-title: J Pharmacol Exp Ther contributor: fullname: Millan MJ – ident: e_1_2_10_11_1 doi: 10.1177/1073858404267382 – ident: e_1_2_10_131_1 doi: 10.1016/S0960-894X(02)00690-X – ident: e_1_2_10_39_1 doi: 10.1074/jbc.M112216200 – ident: e_1_2_10_97_1 doi: 10.1124/jpet.103.061796 – ident: e_1_2_10_72_1 doi: 10.1016/j.neulet.2010.06.036 – ident: e_1_2_10_51_1 doi: 10.1016/j.bbr.2007.12.012 – volume: 260 start-page: 917 year: 1992 ident: e_1_2_10_83_1 article-title: Pharmacological characterization of 5‐hydroxytryptamine‐induced apnea in the rat publication-title: J Pharmacol Exp Ther contributor: fullname: Yoshioka M – ident: e_1_2_10_55_1 doi: 10.1016/0014-2999(83)90230-3 – ident: e_1_2_10_58_1 doi: 10.1073/pnas.90.18.8547 – ident: e_1_2_10_130_1 doi: 10.1021/jm970519e – ident: e_1_2_10_119_1 doi: 10.1046/j.1471-4159.2003.01987.x – ident: e_1_2_10_93_1 doi: 10.1016/j.tips.2009.11.008 – ident: e_1_2_10_24_1 doi: 10.1017/S1461145704004699 – ident: e_1_2_10_48_1 doi: 10.1016/j.pnpbp.2012.08.005 – ident: e_1_2_10_50_1 doi: 10.1016/S0006-8993(99)01311-6 – ident: e_1_2_10_47_1 doi: 10.1124/jpet.104.081919 – ident: e_1_2_10_90_1 doi: 10.1038/nature06612 – ident: e_1_2_10_35_1 doi: 10.1016/0896-6273(93)90149-L – ident: e_1_2_10_107_1 doi: 10.1242/jcs.101337 – ident: e_1_2_10_115_1 doi: 10.1007/BF00176767 – ident: e_1_2_10_40_1 doi: 10.1074/jbc.273.28.17469 – ident: e_1_2_10_59_1 doi: 10.1016/0166-4328(96)00118-0 – ident: e_1_2_10_13_1 doi: 10.1038/sj.tpj.6500340 – ident: e_1_2_10_54_1 doi: 10.1007/s00221-013-3694-y – ident: e_1_2_10_104_1 doi: 10.1124/mol.112.079137 – ident: e_1_2_10_113_1 doi: 10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A – volume: 265 start-page: 5825 year: 1990 ident: e_1_2_10_18_1 article-title: Cloning, functional expression, and mRNA tissue distribution of the rat 5‐hydroxytryptamine1A receptor gene publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)39437-2 contributor: fullname: Albert PR – ident: e_1_2_10_84_1 doi: 10.1016/j.ejphar.2004.01.031 – ident: e_1_2_10_22_1 doi: 10.1046/j.1471-4159.1999.0722238.x – ident: e_1_2_10_85_1 doi: 10.1016/j.neuropharm.2011.08.022 – ident: e_1_2_10_129_1 doi: 10.1021/jm991151j – ident: e_1_2_10_62_1 doi: 10.1016/0006-8993(90)91759-A – ident: e_1_2_10_88_1 doi: 10.1016/S0165-6147(00)01799-5 – ident: e_1_2_10_89_1 doi: 10.1073/pnas.0906695106 – ident: e_1_2_10_21_1 doi: 10.1074/jbc.275.11.8161 – ident: e_1_2_10_96_1 doi: 10.1038/sj.bjp.0705178 – ident: e_1_2_10_8_1 doi: 10.2174/1568007043482633 – ident: e_1_2_10_87_1 doi: 10.1016/j.tips.2005.01.004 – volume: 13 start-page: 5164 year: 1993 ident: e_1_2_10_19_1 article-title: Cloning and differentiation‐induced expression of a murine serotonin1A receptor in a septal cell line publication-title: J Neurosci doi: 10.1523/JNEUROSCI.13-12-05164.1993 contributor: fullname: Charest A – ident: e_1_2_10_34_1 doi: 10.1016/S0021-9258(19)49479-9 – start-page: 26 volume-title: Brain 5‐HT1A receptors year: 1987 ident: e_1_2_10_56_1 contributor: fullname: Dourish CT – volume: 44 start-page: 229 year: 1993 ident: e_1_2_10_36_1 article-title: Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase publication-title: Mol Pharmacol contributor: fullname: Plassat JL – ident: e_1_2_10_118_1 doi: 10.1016/j.neuron.2009.12.003 – ident: e_1_2_10_7_1 doi: 10.1016/j.biopsych.2005.05.012 – ident: e_1_2_10_38_1 doi: 10.1523/JNEUROSCI.1790-05.2005 |
| SSID | ssj0062898 |
| Score | 2.046161 |
| Snippet | Summary
Serotonin (5‐hydroxytryptamine or 5‐
HT
) is an important neurotransmitter regulating a wide range of physiological and pathological functions via... Serotonin (5‐hydroxytryptamine or 5‐ HT ) is an important neurotransmitter regulating a wide range of physiological and pathological functions via activation... |
| SourceID | pubmedcentral crossref |
| SourceType | Open Access Repository Aggregation Database |
| StartPage | 582 |
| SubjectTerms | Review |
| Title | Interplay between Serotonin 5‐ HT 1A and 5‐ HT 7 Receptors in Depressive Disorders |
| URI | https://pubmed.ncbi.nlm.nih.gov/PMC6493079 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La8JAEF7UXnopfVL7kKUUT0ZNsg_36KMiBYuHCN4ku9mlgkaptuCtP6G_sb-ks3nU5tpbQiYQZpad-TbffIPQoxIiUoJIe7wkHeJp5kiXcCfSHas2ooifjG8bv7DRlDzP6KyEaN4Lk5D2lVw04-WqGS9eE27lZqVaOU-sNRn3GRGwNEWrjMrc93OInm6_DBBE0v_GKXUo2GVyQpa-oyCO9k-SnbwHsMMKvfBCPiryIv8kmuEpOskqRNxNv-QMlXR8juqTVGJ638DBoWNq28B1PDmIT-8vUJCyCJfhHmcULAzbwXpnT10x_f78GgXY7eIwjvI7jqF01Bs7dQeDzSCjxn5onCtzbi_RdPgU9EdONjnBUZC_hRO6woCTQuUCHoIEL5XxrXAajYTQ2pZxbWNcjwshteCKMSUoFK6URYxo0zH-FarE61hfI8yVK6UJjdeWHtFcyLar7IUBrKg6oV9FD7n_5ptUIGOeAwvw9zzxdxXxgmd_La24dfEJxDwRuc5ifPPvN2_RMRQ3JKXW3qHK7u1d30MBsZM1dNTtDXrDWrJwfgDBwcnZ |
| link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB1BOcCFHbFjIcSJtE1qx_WxKlQFWtRDQNyq2LFFRUkr2iKVE5_AN_IljLMA5Qa3RJ5ITsax39hv3gCcKCEiJai020vSoZ72HelS7kS6atVGFK0k5dvaN37zll7ds_s5YHkuTELaV7JXjPtPxbj3kHArh0-qlPPESp123acCh6YozcMC_q8ey4P0dAL2MYZIMuA4Yw5Dy0xQyBJ4FHrSniXZ2nsYeFipFz6zIs0yI38sNY0VuMs7mTJMHouTsSyq11_6jX9-i1VYzsAnqaXNazCn43U47aTq1dMzEnwnY43OyCnpfOtaTzcgSAmK_XBKMnYXwZlmMLYbuoR9vL03A-LWSBhH-R0niEr10Bb0IWhznrFuXzTJRT9Hm3DbuAjqTScryuAohAbCCV1hsOehcjHUQuwglalYTTYWCaG1RYhlY1yPCyG14Mr3lWCIiZkf-VSbqqlsQSEexHobCFeulCY0Xll6VHMhy66yFwbDUFUNKztwnDumO0y1N7p5zIKO7CaO3AE-47IvS6ubPduCjkj0s7MPv_vvJ49gsRm0W93W5c31HiwhhqIpg3cfCuPniT5AnDKWh8mo_ARB5Opj |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT8IwGG0UE-OLdyNeG2N4YsC2bqWPBCR4gexhJMQXsnZtJMIgAib45E_wN_pL_LqLgI--bdm3pNvp2vN1p-dD6FYwFgpGuF5e4gaxpGtwk1AjlFXtNiKIHZdva3fcVpc89JzeSqmvWLQv-KAUDUelaPASaysnI1HOdGJlr113CYOuycqTUJU30RZ8sxbNEvVkEHYhj4h3wVHHMRyITk2FtIhHAJr6f5KuvwfJh7Z7oWuz0ro6cmW6ae6h56yhicrktTSf8ZL4-OPh-K8n2Ue7KQnFtSTkAG3I6BAVvMTFelHE_nJT1rSIC9hb-lsvjpCfCBWHwQKnKi8MI854phd2sfP9-dXysVnDQRRmZxQDO5UTXdgHQ0wjVd--S5yZf06PUbd559dbRlqcwRBAEZgRmExB6wNhQsoFHIILZWtvNidkTErNFCtKmRZljEtGhesK5gA3dtzQJVJVlX2CctE4kqcIU2FyrgJlVbhFJGW8Ygp9oCAdFdXAzqObDJz-JPHg6Ge5C4DZj8HMI7oG22-k9s9evwJgxD7a6cs_-_ed12jbazT7T_edx3O0A1SKJELeC5Sbvc3lJdCVGb-KO-YPmKPs4w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interplay+between+Serotonin+5%E2%80%90+HT+1A+and+5%E2%80%90+HT+7+Receptors+in+Depressive+Disorders&rft.jtitle=CNS+neuroscience+%26+therapeutics&rft.au=Naumenko%2C+Vladimir+S.&rft.au=Popova%2C+Nina+K.&rft.au=Lacivita%2C+Enza&rft.au=Leopoldo%2C+Marcello&rft.date=2014-07-01&rft.issn=1755-5930&rft.eissn=1755-5949&rft.volume=20&rft.issue=7&rft.spage=582&rft.epage=590&rft_id=info:doi/10.1111%2Fcns.12247&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_cns_12247 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1755-5930&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1755-5930&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1755-5930&client=summon |